JournalArta
Tuesday, November 17, 2026 · JakartaS&P 7,329.34 ▼1.18%USD/IDR 18,265 ▲0.08%
JournalArta
Global Edition
beyond headlines
Advertisement

Mayo Clinic Study Links Blood Biomarker to Future Cognitive Risk

A Mayo Clinic study found that blood levels of p-tau217, combined with age, sex and genetic risk, may help estimate the chance of mild cognitive impairment or dementia over five or 10 years. The researchers said testing is not currently recommended for people without cognitive symptoms.

By matthew jonathan
November 17, 20262 min read
Mayo Clinic Study Links Blood Biomarker to Future Cognitive Risk
Mayo Clinic Study Links Blood Biomarker to Future Cognitive Risk

A Mayo Clinic study found that a blood biomarker, combined with age, sex and genetic risk, may help estimate a cognitively healthy person’s chance of developing mild cognitive impairment or dementia over five or 10 years. The mayo study blood biomarker analysis linked higher p-tau217 levels and older age with greater risk.

Researchers analyzed 1,644 cognitively unimpaired participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer’s Disease Neuroimaging Initiative. Participants were ages 60 to 90 and had blood measurements, genetic testing and repeated cognitive assessments.

Advertisement

The team developed risk estimates using data from the Mayo Clinic Study of Aging, then checked the link between higher p-tau217 and cognitive decline in the second group.

For a 75-year-old woman who did not carry the APOE e4 genetic risk variant, the estimated five-year risk of mild cognitive impairment was 5% with a relatively low p-tau217 level and 16% with a higher level. Her estimated 10-year risk rose from 12% to 35%.

Age also changed the estimates. At the same high p-tau217 level, the estimated five-year risk of mild cognitive impairment ranged from 6% at age 65 to 37% at age 85.

“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” said Alicia Algeciras-Schimnich, a Mayo Clinic laboratory medicine and pathology researcher and the study’s first author.

Advertisement

The approach builds on earlier Mayo Clinic research that used brain scans to measure amyloid, a protein that accumulates in the brain in Alzheimer’s disease. The researchers said using a blood biomarker is less invasive and could be more scalable.

The findings could matter if therapies under study can prevent or delay cognitive decline before symptoms begin. Prevention trials AHEAD 3-45 and TRAILBLAZER-ALZ 3 are testing amyloid-targeting therapies and used blood biomarkers to help identify participants.

“If preventive therapies prove effective, those numbers could become very important in treatment decisions,” said Ronald Petersen, a Mayo Clinic neurologist and director of the Mayo Clinic Study of Aging.

The risk estimates were developed using one study population and need further evaluation in more diverse groups and with other p-tau217 blood tests. Alzheimer’s biomarker testing is not currently recommended for people without cognitive symptoms.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage
  2. 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI
  3. 3Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds
  4. 4NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur
  5. 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings
Advertisement
Don't Miss

Latest News

All stories →
  1. Markets · StocksWoolworths Share Price on Tuesday: Falls 0.36%, Up 1% in a MonthNov 17
  2. Markets · StocksFortescue Share Price Tumbles 5.55% on Tuesday, Down 10.7% in a MonthNov 17
  3. Markets · StocksBHP Share Price on Tuesday: Slides 4.95%, Near a 3-Month LowNov 17
  4. Sport · More SportsTiger Woods Returns to Competition at Hero World ChallengeNov 17
  5. Advertisement
  6. Sport · More SportsWoods Backs PGA Tour Overhaul Set to Begin in 2028, Rolapp Says No LIV Return PlansNov 17
  7. World · EuropeLloyd Scott, Charity Fundraiser Who Raised More Than £5M, Dies at 65Nov 17
  8. Markets · StocksWall Street Midday: Dow Leads Losses as Chip Shares Slide Before Nvidia EarningsNov 17
  9. WorldAFL Draft Countdown Returns Wednesday Before Two Nights of PicksNov 17